Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver cancer
Hundreds of people with advanced liver cancer (also called hepatocellular carcinoma or HCC) are set to benefit after NICE today (26 February 2021) published final draft guidance recommending a cancer treatment called selective internal radiation therapy (SIRT) as an option for treating the condition
-
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE today (26 February) recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).
-
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
-
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
